Startups

TTTTT

Our startups

Be inspired. Search our startups.

Filter
Diamond Winners
2013 Boston Diamond Winner

In the US, over half a million patients suffer from chronic kidney failure (CKF). Most are dependent on hemodialysis to filter their blood. Unfortunately, more than 100,000 patients/year die from CKF, a large reason being the failure of the interface between the patient and the hemodialysis machine known as a “vascular access”. At Hemova, we have developed a blood access device that is safer and more reliable than current solutions; helping to keep our patients healthier and prolong their lives.

Gold Winners
2017 Boston Gold Winner

There is a crisis in medical imaging. Current MRI contrast agents (GBCAs) contain toxic gadolinium. GBCAs cause brain deposition of gadolinium in all patients, and pose devastating risks to renally impaired patients. Each year over 4 million very sick patients worldwide must be denied crucial diagnostic imaging, and over 30 million patients are put at risk.
Reveal solves this >$1B problem with a biocompatible gadolinium-free contrast agent that is a safe, direct substitute for GBCAs.

2017 Switzerland Gold Winner

Heart failure as a consequence of myocardial fibrosis is the world’s biggest killer and represents a significant unmet medical need. No therapies currently exist that either directly target the heart or the fibrotic process itself. We have discovered a heart specific regulator of fibrosis – the long noncoding RNA, Wisper. By using our first-in-class proprietary approach to target Wisper, we are able to block myocardial fibrosis and treat heart failure in pre-clinical animal models.

2015 Boston Gold Winner

LaunchPad Medical is developing Tetranite™, a bone adhesive that is gradually replaced by bone. Such a product has significant load-bearing strength and will provide a new tool for the surgeon to anchor metal implants, fill voids, and fix bone fragments back together while keeping procedures simpler, safer, and less expensive. Tetranite™ has a combination of strength, biocompatibility, and low cost to be commercially viable. The dental implant market will be the initial platform application.

2014 Boston Gold Winner

For many diseases whose treatment involves frequent delivery of injectable drugs (diabetes, Parkinson's, osteoporosis, etc.), using continuous infusion pumps often leads to better outcomes than multiple daily injections, resulting in healthier patients and lower healthcare costs. Existing pumps' limitations, however, inhibit their adoption. Our Evopump - a more comfortable, precise, therapeutically flexible, and lower cost pump - should significantly increase adoption, yielding better outcomes

2013 Boston Gold Winner

Burns and other skin tissue losses are currently treated with partial thickness skin grafts from healthy skin, a painful procedure that generates additional scarring and has to be performed in an OR under anesthesia carrying complications inherent to surgical procedures. KERADERM consists of 4×4in Skin-cell-coated sheets, cultured from a 5mm healthy skin sample of the same patient. It is a painless, non-surgical procedure that heals in a short period of time with a significant decrease in cost

Sidecar Winners
2016 Boston Sidecar Winner

LambdaVision is developing a protein-based retinal implant to restore vision to the tens of millions blinded by age-related macular degeneration and retinitis pigmentosa. There is no cure for these diseases and current treatments only slow their progression, and people are going blind. LambdaVision's flexible, minimally-invasive, subretinal design, is the first to use a photoactive protein to replace the function of the damaged photoreceptor cells to provide high-resolution vision.

2016 Boston Sidecar Winner

Some people are thinner than others, and DLS has identified a mutation in humans that causes thinness. The mutation in the target protein causes loss-of-function leading to the wasting of energy in the body and results in thinness. DLS is in the process of creating a small molecule inhibitor to the target protein that will similarly cause an inefficient metabolism and lead to thinness regardless of the cause of obesity. Following nature's example provides a safer path to curing obesity.

2016 Boston Sidecar Winner

Angiex is pioneering a new approach to cancer therapy: vascular targeting. Angiex is making an antibody-drug conjugate (ADC) therapy against a novel target expressed by tumor endothelial cells and by most tumor cells.

In preclinical studies, Angiex ADCs have shown an ability to regress human xenograft and mouse syngeneic tumors. If toxicity to the normal vasculature can be limited, Angiex's ADC has the potential to provide an effective treatment for all solid tumors.

2013 Boston Sidecar Winner

Vecoy Nanomedicines develops novel nanomedicines for the treatment of HIV/AIDS and other viral infections, using nano-scale virus traps that mimic human cells that lure and destroy viruses. This disruptive approach will revolutionize anti-viral medicine and can save the lives of millions.
The company has secured angel investments, filed a patent application (PCT), accomplished a technological proof of concept and won 1st place at the FutureMed biotech startup event in California on 2013.

Silver Winners
2017 Boston Silver Winner

47% of all dogs over the age of 10 will die from cancer. With current treatment options expensive and potentially leading to negative side effects, VetiVax is a novel, personalized immunotherapy that uses the animals’ own tumor cells to fight the cancer.

Using a surgically excised portion of tumor tissue, we create a series of treatments that are given back to the animal to help stimulate their immune system to fight cancer, safely and inexpensively.

2017 Boston Silver Winner

ReviveMed is a precision-medicine platform that leverages the data from small molecules or metabolites. ReviveMed technology, which was developed at MIT and published in Nature Methods, uniquely overcomes the difficulty of using a large set of metabolomic data, and transform these data into actionable insight. Currently, we selected a few strategic clients from leading pharma/biotech companies to provide them with drug de-risking, biomarker discovery and therapeutic solutions.

2015 UK Silver Winner

RE-VANA is working on new drug delivery systems that can provide significant long-term benefits for patients who are suffering from severe eye diseases that can lead to blindness. The new systems that we are developing will enhance patient comfort and improve their vision, which will eventually reduce the burden on healthcare services, patients and care givers.

2015 Boston Silver Winner

Cogentis Therapeutics is developing a drug to treat a family of neurodegenerative disorders, including Alzheimer's Disease, Pick's Disease, and our initial target condition, Frontotemporal Degeneration, also known as Frontotemporal Dementia (FTD).

Our drug can cross into the brain and prevent the process which leads to neural decay, dementia, and cell death. Due to advances in medical technology, we can target a previously inaccessible pathway and disrupt FTD before it begins.

2014 Boston Silver Winner

Diagnostic of diseases is a 40 billion USD global market where current technologies are expensive, require specialized equipment and take several hours to produce results, affecting billions around the world mostly in developing countries. We developed a 5 minute and $1 diagnostic technology for infectious diseases that allows health data collection and analysis in real time for disease surveillance, using big data algorithms to help decision makers to create strategies for disease control.

2014 Boston Silver Winner

Oncolinx is developing the next generation of antibody-drug conjugates (ADCs)--powerful, targeted cancer therapies that have dramatically fewer side effects. These therapies can be targeted to nearly any type of cancer, and are rapidly becoming the state-of-the-art in cancer treatment. Drawing on the scientific innovation of the National Cancer Institute, the world's leading biotechs and life sciences companies, Oncolinx is redefining the paradigm of cancer therapy.

2013 Boston Silver Winner

Leveraging our strengths in high-throughput screening technology we provide the fastest methods for directed studies of in vivo gene function which results in earlier identification of therapeutic targets. In combination with the rapid development time of small model organisms (4 days) our systems enable rapid iterations to shorten drug development times. We generate humanized transgenic models for mechanism of drug action studies preventing costly drug failures in later stages.

2013 Boston Silver Winner

Cystic Fibrosis (CF) is an inherited lung disease with 30,000 US patients with a life expectancy of 37. There is no treatment for 96% of patients and a high unmet clinical need. Novel inhaled lead drug, Procaftor, shows clinically predictive efficacy in a human CF model. CF is an orphan disease with a lean development model. Our experienced CF drug development team are asking for a $8m to fund a 3 year IND to end of Phase 2a with several investor exits. We anticipate peak US sales of $1.2bn.

2012 Boston Silver Winner

Stress is a silent killer. Where objective data is now critical throughout medicine and daily life, diagnoses and treatments of stress rely exclusively on subjective reports to evaluate symptom severity and trends. Neumitra (noo-MEE-tra) helps monitor and manage acute and chronic stress with wearable and mobile technologies for health, performance, and happiness. We compute recurring reports of personalized health to aggregate analytics from one person to thousands. Together we’ll solve stress.

2012 Boston Silver Winner

Cancer is diagnosed today much too late: increasing sensitivity by thousand folds, Akrivis’ Z-TECT technology will allow cancer detection so early that it will be cured faster and with less toxic drugs. Z-TECT can achieve this with blood tests or medical imaging of mm-sized tumors. After selling custom reagents to repeat customers for a year, Akrivis recently signed a worldwide distribution agreement and seeks $250k to hire 2 scientists and accelerate the launch of its first products by Q1 2013

Startups
2017 Boston Silver Winner

47% of all dogs over the age of 10 will die from cancer. With current treatment options expensive and potentially leading to negative side effects, VetiVax is a novel, personalized immunotherapy that uses the animals’ own tumor cells to fight the cancer.

Using a surgically excised portion of tumor tissue, we create a series of treatments that are given back to the animal to help stimulate their immune system to fight cancer, safely and inexpensively.

2017 Boston Silver Winner

ReviveMed is a precision-medicine platform that leverages the data from small molecules or metabolites. ReviveMed technology, which was developed at MIT and published in Nature Methods, uniquely overcomes the difficulty of using a large set of metabolomic data, and transform these data into actionable insight. Currently, we selected a few strategic clients from leading pharma/biotech companies to provide them with drug de-risking, biomarker discovery and therapeutic solutions.

2017 Boston Gold Winner

There is a crisis in medical imaging. Current MRI contrast agents (GBCAs) contain toxic gadolinium. GBCAs cause brain deposition of gadolinium in all patients, and pose devastating risks to renally impaired patients. Each year over 4 million very sick patients worldwide must be denied crucial diagnostic imaging, and over 30 million patients are put at risk.
Reveal solves this >$1B problem with a biocompatible gadolinium-free contrast agent that is a safe, direct substitute for GBCAs.

2017 Switzerland Gold Winner

Heart failure as a consequence of myocardial fibrosis is the world’s biggest killer and represents a significant unmet medical need. No therapies currently exist that either directly target the heart or the fibrotic process itself. We have discovered a heart specific regulator of fibrosis – the long noncoding RNA, Wisper. By using our first-in-class proprietary approach to target Wisper, we are able to block myocardial fibrosis and treat heart failure in pre-clinical animal models.

2016 Boston Sidecar Winner

LambdaVision is developing a protein-based retinal implant to restore vision to the tens of millions blinded by age-related macular degeneration and retinitis pigmentosa. There is no cure for these diseases and current treatments only slow their progression, and people are going blind. LambdaVision's flexible, minimally-invasive, subretinal design, is the first to use a photoactive protein to replace the function of the damaged photoreceptor cells to provide high-resolution vision.

2016 Boston Sidecar Winner

Some people are thinner than others, and DLS has identified a mutation in humans that causes thinness. The mutation in the target protein causes loss-of-function leading to the wasting of energy in the body and results in thinness. DLS is in the process of creating a small molecule inhibitor to the target protein that will similarly cause an inefficient metabolism and lead to thinness regardless of the cause of obesity. Following nature's example provides a safer path to curing obesity.

2016 Boston Sidecar Winner

Angiex is pioneering a new approach to cancer therapy: vascular targeting. Angiex is making an antibody-drug conjugate (ADC) therapy against a novel target expressed by tumor endothelial cells and by most tumor cells.

In preclinical studies, Angiex ADCs have shown an ability to regress human xenograft and mouse syngeneic tumors. If toxicity to the normal vasculature can be limited, Angiex's ADC has the potential to provide an effective treatment for all solid tumors.

2015 UK Silver Winner

RE-VANA is working on new drug delivery systems that can provide significant long-term benefits for patients who are suffering from severe eye diseases that can lead to blindness. The new systems that we are developing will enhance patient comfort and improve their vision, which will eventually reduce the burden on healthcare services, patients and care givers.

2015 Boston Gold Winner

LaunchPad Medical is developing Tetranite™, a bone adhesive that is gradually replaced by bone. Such a product has significant load-bearing strength and will provide a new tool for the surgeon to anchor metal implants, fill voids, and fix bone fragments back together while keeping procedures simpler, safer, and less expensive. Tetranite™ has a combination of strength, biocompatibility, and low cost to be commercially viable. The dental implant market will be the initial platform application.

2015 Boston Silver Winner

Cogentis Therapeutics is developing a drug to treat a family of neurodegenerative disorders, including Alzheimer's Disease, Pick's Disease, and our initial target condition, Frontotemporal Degeneration, also known as Frontotemporal Dementia (FTD).

Our drug can cross into the brain and prevent the process which leads to neural decay, dementia, and cell death. Due to advances in medical technology, we can target a previously inaccessible pathway and disrupt FTD before it begins.

2014 Boston Silver Winner

Diagnostic of diseases is a 40 billion USD global market where current technologies are expensive, require specialized equipment and take several hours to produce results, affecting billions around the world mostly in developing countries. We developed a 5 minute and $1 diagnostic technology for infectious diseases that allows health data collection and analysis in real time for disease surveillance, using big data algorithms to help decision makers to create strategies for disease control.

2014 Boston Silver Winner

Oncolinx is developing the next generation of antibody-drug conjugates (ADCs)--powerful, targeted cancer therapies that have dramatically fewer side effects. These therapies can be targeted to nearly any type of cancer, and are rapidly becoming the state-of-the-art in cancer treatment. Drawing on the scientific innovation of the National Cancer Institute, the world's leading biotechs and life sciences companies, Oncolinx is redefining the paradigm of cancer therapy.

2014 Boston Gold Winner

For many diseases whose treatment involves frequent delivery of injectable drugs (diabetes, Parkinson's, osteoporosis, etc.), using continuous infusion pumps often leads to better outcomes than multiple daily injections, resulting in healthier patients and lower healthcare costs. Existing pumps' limitations, however, inhibit their adoption. Our Evopump - a more comfortable, precise, therapeutically flexible, and lower cost pump - should significantly increase adoption, yielding better outcomes

2013 Boston Sidecar Winner

Vecoy Nanomedicines develops novel nanomedicines for the treatment of HIV/AIDS and other viral infections, using nano-scale virus traps that mimic human cells that lure and destroy viruses. This disruptive approach will revolutionize anti-viral medicine and can save the lives of millions.
The company has secured angel investments, filed a patent application (PCT), accomplished a technological proof of concept and won 1st place at the FutureMed biotech startup event in California on 2013.

2013 Boston Gold Winner

Burns and other skin tissue losses are currently treated with partial thickness skin grafts from healthy skin, a painful procedure that generates additional scarring and has to be performed in an OR under anesthesia carrying complications inherent to surgical procedures. KERADERM consists of 4×4in Skin-cell-coated sheets, cultured from a 5mm healthy skin sample of the same patient. It is a painless, non-surgical procedure that heals in a short period of time with a significant decrease in cost

2013 Boston Diamond Winner

In the US, over half a million patients suffer from chronic kidney failure (CKF). Most are dependent on hemodialysis to filter their blood. Unfortunately, more than 100,000 patients/year die from CKF, a large reason being the failure of the interface between the patient and the hemodialysis machine known as a “vascular access”. At Hemova, we have developed a blood access device that is safer and more reliable than current solutions; helping to keep our patients healthier and prolong their lives.

2013 Boston Silver Winner

Leveraging our strengths in high-throughput screening technology we provide the fastest methods for directed studies of in vivo gene function which results in earlier identification of therapeutic targets. In combination with the rapid development time of small model organisms (4 days) our systems enable rapid iterations to shorten drug development times. We generate humanized transgenic models for mechanism of drug action studies preventing costly drug failures in later stages.

2013 Boston Silver Winner

Cystic Fibrosis (CF) is an inherited lung disease with 30,000 US patients with a life expectancy of 37. There is no treatment for 96% of patients and a high unmet clinical need. Novel inhaled lead drug, Procaftor, shows clinically predictive efficacy in a human CF model. CF is an orphan disease with a lean development model. Our experienced CF drug development team are asking for a $8m to fund a 3 year IND to end of Phase 2a with several investor exits. We anticipate peak US sales of $1.2bn.

2012 Boston Silver Winner

Stress is a silent killer. Where objective data is now critical throughout medicine and daily life, diagnoses and treatments of stress rely exclusively on subjective reports to evaluate symptom severity and trends. Neumitra (noo-MEE-tra) helps monitor and manage acute and chronic stress with wearable and mobile technologies for health, performance, and happiness. We compute recurring reports of personalized health to aggregate analytics from one person to thousands. Together we’ll solve stress.

2012 Boston Silver Winner

Cancer is diagnosed today much too late: increasing sensitivity by thousand folds, Akrivis’ Z-TECT technology will allow cancer detection so early that it will be cured faster and with less toxic drugs. Z-TECT can achieve this with blood tests or medical imaging of mm-sized tumors. After selling custom reagents to repeat customers for a year, Akrivis recently signed a worldwide distribution agreement and seeks $250k to hire 2 scientists and accelerate the launch of its first products by Q1 2013